Clinical Trial

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria

Investigator
Complete title:
A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Erythropoietic Protoporphyria or X-Linked Protoporphyria
Trial phase:
Phase III
Study ID:
NCT04402489
Local study ID:
RG1007171
Summary:
The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, or stinging) associated with sunlight exposure in subjects with EPP or XLP aged 12-75.
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Trial exclusions
Other exclusion criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us
phone 1-800-606-7800
Toll-free